Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
NCT00954512 · Merck Sharp & Dohme LLC · PHASE1/PHASE2 · terminated · last registry update 2018-08-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was terminated for business reasons.” | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TOP2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-08-07Phase 3 first posted: National Institute of Allergy and Infectious Diseases (NIAID), Best Available Therapy (BAT) (NCT04047628)
- 2019-07-24Phase 3 first posted: European Organisation for Research and Treatment of Cancer - EORTC, Preoperative chemotherapy (NCT04031677)
- 2019-06-13Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT03984448)
- 2019-04-16Phase 3 first posted: National Cancer Institute (NCI), Asparaginase Erwinia chrysanthemi + Blinatumomab (NCT03914625)
- 2019-04-09Phase 3 first posted: National Cancer Institute (NCI), Brentuximab Vedotin + Dacarbazine (NCT03907488)
- 2019-01-30Results posted on the registry: St. Jude Children's Research Hospital, Induction Chemotherapy + Low-Risk Therapy (NCT00602667)
- 2018-08-29Phase 3 first posted: ARCAGY/ GINECO GROUP, Niraparib + Niraparib + TSR-042 (Dostarlimab) (NCT03651206)
- 2018-05-23Phase 3 first posted: Children's Oncology Group, Carboplatin + Cisplatin (NCT03533582)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision